CD13—not just a marker in leukemia typing (original) (raw)
Related papers
Journal of Clinical Pathology, 1994
To provide a detailed knowledge of the distribution of the CD13 molecule, also known as the protease aminopeptidase-N, on both normal tissues and malignant neoplasms of epithelial and lymphoid origin. CD13 antigen was examined by immunocytochemistry, using a recently produced antibody (VS5E) alongside a commercially available anti-CD13 monoclonal antibody. The VS5E recognising CD13 was produced by immunising a doxorubicin resistant breast cancer cell line (MCF-7-ADr). A striking feature of this antibody was that it stained the doxorubicin resistant cells but not the parental cell line. Both antibodies were tested on a broad range of normal tissues and three common types of epithelial malignancy (colon n = 28, lung n = 30, breast n = 35), and 12 cases of Hodgkin's and 52 of non-Hodgkin's lymphomas. CD13 was expressed on many tissue and cell types outside the haematopoietic system. In particular it was present on breast epithelium and in 20% (seven of 35) of breast carcinomas, but absent in normal and neoplastic colonic and bronchial tissues and lymphomas. This study provides not only detailed information about the expression of the CD13 antigen, but also raises the important possibility that CD13 expression may correlate with drug resistance in breast carcinomas.
CD13 is dispensable for normal hematopoiesis and myeloid cell functions in the mouse
Journal of Leukocyte Biology, 2010
While the myeloid marker CD13 has been implicated in numerous myeloid cell functions, its genetic ablation reveals a nominal contribution of CD13 to these functions. The robust and consistent expression of the CD13 cell surface marker on very early as well as differentiated myeloid hematopoietic cells has prompted numerous investigations seeking to define roles for CD13 in myeloid cells. To address the function of myeloid CD13 directly, we created a CD13 null mouse and assessed the responses of purified primary macrophages or DCs from WT and CD13 null animals in cell assays and inflammatory disease models, where CD13 has been implicated previously. We find that mice lacking CD13 develop normally with normal hematopoietic profiles except for an increase in thymic but not peripheral T cell numbers. Moreover, in in vitro assays, CD13 appears to be largely dispensable for the aspects of phagocytosis, proliferation, and antigen presentation that we tested, although we observed a slight d...
Study of Myeloid Antigens CD 13 and CD 33 Expression in Sudanese Patients with Acute Leukemia
2015
Background: Acute leukemia is a heterogeneous group of malignancies which are varying according to their clinical, morphologic, immunologic, and molecular features and display different characteristic patterns of surface antigen expression. This 1 Corresponding author: ahmed_siddig@ymail.com Ahmed S.Adam, Enaam A. Abdelgader, Osama A. Altayeb, Eman Abbass F., Amin A. Al-Amin, Rasha Abdelgleel, Tarig M. Karfis, Eldirdiri M. Abdelrahman, Osman H. MusaStudy of Myeloid Antigens CD13 and CD33 Expression in Sudanese Patients with Acute Leukemia EUROPEAN ACADEMIC RESEARCH Vol. III, Issue 6 / September 2015 6402 study was conducted to study the myeloid antigens CD13 & CD33 expression in Sudanese patients with acute leukemia attended the Flowcytometry Laboratory in Khartoum, Sudan. Materials and Methods: It was a descriptive cross-sectional study. Flowcytometry was used for immunophenotyping of acute leukemia using bone marrow or peripheral blood samples for the analysis. All samples prepare...
Blood, 2000
Expression of CD13/N-aminopeptidase may reflect cell activation and growth. We examined its role regarding cell growth in cultures of cord blood CD34(+) cells with stem cell factor/Flt-3 ligand/granulocyte-macrophage colony-stimulating factor/tumor necrosis factor-alpha. Indeed, 82% +/- 6% of cells from culture day 5 were CD13(hi), 25% +/- 8% of which were still Lin-. About 50% of CD13(hi)Lin- cells, which comprise progenitors of dendritic cells (DC), monocytes/macrophages and granulocytes, and 30% of CD13(lo)Lin- cells were CD34(+). Sorted CD34(+)CD13(hi)Lin- cells, cultured further for 7 days with the same cytokines, expanded 31-fold and CD34(-)CD13(hi)Lin- cells 7-fold, but CD34(+)CD13(lo)Lin- and CD34(-)CD13(lo)Lin- cells did not grow. Thus, cell growth correlated with CD13 expression, all the more so that cells were CD34(+). Actinonin, the most potent N-aminopeptidase inhibitor, was used to engage CD13 on sorted CD13(hi)Lin- cells and on culture day-7 bulk cells. In both cases,...